Abstract
We have performed a screening of differential methylation of 100 genomic loci in 100 breast cancer samples by use of our ABC (Amplification of intermethylated sites, Bioinformatics, Capillary electrophoresis) protocol. This novel method for unbiased screening of differential methylation has allowed us to identify abnormal methylation of CpG islands associated with the AX746725, AK127124, TMEM176A, TMEM176B, ATP2B4, C12orf32, KIAA1324L, C2CD2, ITGA9, IQSEC2, PFH15, PURB, ATMIN, and ASCL2 genes, EST CN371412, and intergenic CpG islands located on 13q32.1 and Xq25. Abnormal methylation frequencies of the listed loci in breast cancer vary from 2% to 66%. Preliminary estimation of these methylation markers by cluster analysis has revealed five distinct groups. In order to estimate clinical significance of the markers we performed multidimensional correspondence analysis for each of the clusters. Methylation of KIAA1324L and ATP2B4 genes is associated with histological types of tumors: methylated status groups with ductal carcinoma, unmethylated groups with mixed type. Methylation of KIAA1324L and ATP2B4 genes is associated with breast cancer stage 2B. PHF15, IQSEC2, C2CD2, AX746725/AK127124, ATMIN, and PURB genes and the intergenic CpG island on 13q32.1 indicate an association of unmethylated status with grade 2 and stage 2. Methylation of IQSEC2, 13q32.1 CpG island, and PURB may be associated with tumor stage 4. Frequency distribution of methylation indices calculated for the genes and loci identified in this study naturally divides the breast cancer samples into low-methylated and high-methylated tumors. The high-methylated group exhibits significant associations with ductal breast carcinoma and tumor grade 4. Low methylation indices are associated with a mixed histological type and tumor stage 1. This research was supported by Friends for an Earlier Breast Cancer Test (USA); Russian Foundation for Basic Research (grant 08-0401685-а); and the Federal Target Program “Scientific and scientific-educational personnel of innovation Russia” of the Federal Science and Innovations Agency (Rosnauka), contract no. 02.740.11.0089. METHYLATION AND DELETION OF DNA MISMATCH REPAIR GENES IN TUMORAL CELLS AND NORMAL GASTRIC MUCOSA IN PATIENTS WITH GASTRIC ADENOCARCINOMAS
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
